People on the Move
Histogenics
Histogenics, a regenerative medicine company focused on musculoskeletal therapies, has appointed Kathleen Large to VP of Clinical Operations. She will be responsible for managing the company’s clinical programmes, including the ongoing Phase 3 trial of NeoCart, a treatment for knee cartilage injuries which uses the patient’s own cartilage cells.
Before joining Histogenics, Large was Director, Early Stage Development and Strategic Site Alliances at Millennium Pharmaceuticals (Takeda’s oncology subsidiary). She has also served in strategic and leadership positions at Eli Lilly, Quintiles, INC, and University Hospitals of Cleveland.